A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

    Study Chairs:
    Prof. Dr. med. Gunter von Minckwitz - Düsseldorf, Germany
    Jose Baselga, MD, PhD - Boston, MA
    José Bines, MD - Rio de Janeiro, Brazil


    IBCSG Study Chair:
    Prof. Guy Jéruslem, Liège, Belgium

    Statisticians:
    Ian Bradbury, PhD - Kincraig, Scotland

    Lead Trial Coordinator:
    Holly Shaw

    Trial Monitor
    Giuseppe Achille

    IBCSG Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Data Management

    Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation:
    October 4, 2011

    Targeted Accrual:
    3806 patients

    Final Accrual
    4805 patients

    Date of closure

    August 31, 2013

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login